Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2022 | What to look forward to at ASCO 2022

Parag Jasani • 30 May 2022
ASCO 2022
Chronic Lymphocytic Leukemia Leukemia

Parag Jasani, MBBS, MRCP, FRCPath, FRCP, University College Hospital, London, UK, on what he is looking forward to at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting 2022. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Parag Jasani

The key barrier to making the implementation of bispecific antibodies in CLL possible 0:41
The key barrier to making the implementation of bispecific antibodies in CLL possible
Parag Jasani • 14 Sep 2025
Investigating bispecific antibodies in CLL 1:00
Investigating bispecific antibodies in CLL
Parag Jasani • 14 Sep 2025
The potential of bispecific antibodies in CLL 1:04
The potential of bispecific antibodies in CLL
Parag Jasani • 14 Sep 2025
Personalizing CLL therapy in the frontline 0:56
Personalizing CLL therapy in the frontline
Parag Jasani • 10 Dec 2023

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals